Lonza is investing CHF 20 million in GMP laboratories and mid-scale manufacturing assets at its API manufacturing center in Nansha, China. The investment will allow Lonza to provide a smoother transition from small-scale to large-scale manufacturing for customers.   The expansion will include six 1,000L small molecule reactors, four 1,500L vessels, and isolation equipment providing mid-scale capacity to bridge between early-phase and late-phase production. The additional GMP labs will be able ...